Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
NCT ID: NCT00408954
Last Updated: 2010-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
27 participants
INTERVENTIONAL
2007-03-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
UK-369,003
UK-369,003-100 mg MR formulation for 2 weeks
UK-369,003
UK-369,003
100 mg MR tablet once daily for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UK-369,003
100 mg MR tablet once daily for 2 weeks
UK-369,003
UK-369,003-100 mg MR formulation for 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of BPH
* Qmax 5 to 15 ml/sec with a voided volume of ≥150 ml
* Urodynamically defined bladder outlet obstruction
Exclusion Criteria
* Post-void residual urine volume \>200 ml
* Documented UTI
* History of relevant urological surgery
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
Hradec Králové, , Czechia
Pfizer Investigational Site
Olomouc, , Czechia
Pfizer Investigational Site
Ústí nad Labem, , Czechia
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
Bratislava, Slovakia, Slovakia
Pfizer Investigational Site
Martin, Slovakia, Slovakia
Pfizer Investigational Site
Trenčín, Slovakia, Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3711045
Identifier Type: -
Identifier Source: org_study_id